BioCryst Pharmaceuticals Inc
BCRX
NASDAQ
Biotechnology
$9.74
USD
-0.07 (-0.71%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $2.52B
Volume 3.8M
Revenue
$940.61M
TTM
+68.7%
YoY
Gross Margin
98%
TTM
+0.8%
YoY
Net Income
$-384.67M
TTM
-977.2%
YoY
Operating Cash Flow
$376.13M
TTM
+2136.6%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 163.4 | 159.4 | 406.6 | 156.4 | 218.3 |
YoY Growth | +49.4% | +36.1% | +209.1% | +7.5% | +33.6% |
Cost of Revenue | 2.8 | 2.2 | 9.5 | 5.4 | 3.8 |
Gross Profit | 160.6 | 157.2 | 397.0 | 151.0 | 214.4 |
Selling, General & Administrative | 87.4 | 83.0 | 95.8 | 94.6 | 64.0 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 130.8 | 127.6 | 136.6 | 852.6 | 115.9 |
Operating Income | 29.8 | 29.6 | 260.4 | -701.6 | 98.5 |
EBITDA | 30.1 | 29.9 | 260.8 | -700.5 | 98.4 |
Other Income / Expense | -4.2 | -0.0 | -1.1 | -1.7 | 0.3 |
Total Other Income / Expense | -23.3 | -17.5 | -12.4 | -19.2 | -19.0 |
Income Before Income Taxes | 6.5 | 12.1 | 248.0 | -720.8 | 79.5 |
Income Taxes | 1.4 | -0.8 | 2.2 | 1.0 | 1.1 |
Net Income | 5.1 | 12.9 | 245.8 | -721.8 | 78.4 |
Consolidated Net Income / Loss | 5.1 | 12.9 | 245.8 | -721.8 | 78.4 |
Net Income Attributable to Common Shareholders | 5.1 | 12.9 | 245.8 | -721.8 | 78.4 |
Basic EPS | $0.02 | $0.06 | $1.17 | -$2.98 | $0.31 |
Diluted EPS | $0.02 | $0.06 | $1.12 | -$2.98 | $0.30 |
Basic Shares Outstanding | 209.5M | 210.2M | 211.0M | 242.3M | 254.5M |
Diluted Shares Outstanding | 219.9M | 219.9M | 219.3M | 242.3M | 265.2M |